Research highlights Treatment options for myeloma bone disease have increased during the last years. Denosumab is an RANKL inhibitor that has shown its noninferiority in SRE prevention compared to zoledronic acid. Denosumab may constitute a safer option for patients with…
Research highlights Myeloma growth leads to an imbalance of osteoclasts and osteoblasts causing osteolytic bone disease. Multiple cell types within the bone marrow influence myeloma cell colonization, survival, and growth or dormancy. Repairing existing bone lesions remains a current challenge…
Research highlights Bone is the preferred site of metastasis in breast cancer, especially in ER/PR-positive tumors CDK4/6 inhibitors combined with aromatase inhibitors/fulvestrant prolong PFS including in patients with bone metastases In HER2-positive patients with bone metastases new combined therapies and…
Intended figures 1. PSMA PET/CT-illustrating scan of both skeletal and local recurrence 2. “Dual-alpha technology” Introduction When treating patients with primary bone cancers and bone metastatic disease, clinicians need to consider best combinations of the various treatments available. Optimal management…
Introduction Prostate cancer (PCa) is the most common cancer in the United States, and its incidence is likely to continue to increase with the increasingly aging population. Majority of patients presents a localized PCa, while less than 5% of patients…
Multidisciplinary management of bone metastases In general, the treatment of bone metastases is aimed at palliating symptoms, with cure only rarely a realistic aim in a few rare malignancies such as lymphoma or germ cell tumors affecting bone. Treatments vary…
Introduction One of the first to observe the propensity of breast cancers to form bone metastases was the surgeon, Stephen Paget, who described the site distribution of metastases in 735 cases of breast cancer proposing that the association of metastases…
Introduction Bisphosphonates (BPs) are well established as the gold standard treatment for metabolic bone diseases associated with excessive bone destruction, including osteoporosis, bone metastases, and cancer therapy–induced bone loss. By virtue of their ability to chelate calcium ions, BPs bind…
Introduction Bone metastasis is common and is one of the leading causes of complications in the natural history of cancer. The consequences of bone metastasis may compromise quality of life, limit day-to-day activities, threaten life expectancy, and increase medical intervention…
The definition of palliative care In 1990, the WHO defined this term as the active and holistic care of patients with advanced or progressive diseases, including the treatment of pain and other symptoms; it also included aspects of the evolutionary…